Tumorigenesis in the mouse mammary gland and in the human breast is considered to be the result of sequential changes that accumulate over time. The changes in the mammary epithelium can be detected at the subgross and histological levels as hyperplasias with varying degrees of atypia (1) (2) (3) , at the gene level with both gain and loss of gene expression (1, 3, 4) , and at the chromosomal level as the gain or loss of chromosomes (i.e., aneuploidy) by cytogenetic or comparative genomic hybridization (CGH) methods (5-7). DNA content changes, i.e., loss of heterozygosity (LOH) and aneuploidy, can be detected at early stages of morphological atypia, supporting the hypothesis that aneuploidy is a critical event driving neoplastic development and progression (8, 9) . In contrast to human breast cancers, most mammary cancers induced in traditional models of mice and rats appear to be diploid and/or show very low frequency of LOH (10) .
Aneuploidy is the gain or loss of chromosomes; it is a dynamic, progressive, and accumulative event that is almost universal in solid tumors and occurs early in neoplastic development (11) (12) (13) (14) . The chromosome imbalance occurring in aneuploid cell populations results in altered gene dosage, gene balance, and loss of heterozygosity, common events associated with tumorigenesis. Consequences of these events include alterations in cellular metabolic control (15) , transcriptional regulation, and signal transduction (reviewed in ref 14) . The extensive array of altered gene expression observed in tumors and the numerous altered chromosomes detected by CGH (5) (6) (7) (8) provide striking evidence that aneuploidy can totally disrupt cell homeostatic control.
The question of whether aneuploidy is a consequence of neoplastic development or a cause of neoplastic development is currently being debated (14 -17) . It is likely that this question will be unresolved until the mechanisms generating aneuploidy are understood at the molecular level. One mechanism that has been proposed for generating aneuploidy is failure to appropriately segregate chromo-somes (14, 16, 17) . The processes of chromosome segregation and movement are well defined at a cellular level, but molecular events that interfere with appropriate chromosome segregation and resulting in aneuploidy are not well understood and are likely to involve multiple targets. For instance, one can conceive of interference with mitotic spindle dynamics, abnormal centrosome duplication, altered chromosome condensation and cohesion, defective centromeres, and loss of mitotic checkpoints as being events generating aneuploidy (reviewed in ref 14) .
One well-known and important regulator of the cell cycle is the tumor suppressor gene p53 (18, 19) . The loss or mutation of p53 results in tumorigenesis, aneuploidy, and centrosome amplification (20 -23) . Centrosome anomalies have been reported for a variety of solid tumors and in tumor-derived cell lines (22) (23) (24) (25) (26) (27) (28) . Defects affect spindle polarity, microtubule nucleation, abnormal centrosome duplication, and centrosome separation during mitosis. Functional consequences of centrosome defects may play a role during neoplastic transformation and tumor progression, increasing the incidence of multipolar mitoses that lead to chromosomal segregation abnormalities and aneuploidy.
Recently, a p53 null mammary epithelial cell model has been developed (29, 30) . The absence of p53 expression does not alter normal mammary gland development but does result in a markedly increased incidence of tumorigenesis. The mammary tumors are frequently aneuploid and the tumorigenic process is markedly increased by chronic hormone stimulation (30) .
Both estrogen and progesterone are critical hormones in mammary development in rodents and humans (31) . While estrogen is essential for ductal outgrowth (31, 32) , progesterone is essential for tertiary branching and alveolar morphogenesis (33, 34) . The importance of progesterone as a mitogen, as well as a morphogen, for mammary development has been reemphasized recently with the demonstration that progesterone stimulates DNA synthesis and mammary morphogenesis in ovariectomized mice (35) . Antiprogestins also inhibit mammary epithelial cell growth (36) . In chemical carcinogen-induced mouse mammary tumorigenesis, progesterone is the critical hormone required for tumorigenesis (37, 38) . In human breast cancer, there is recent compelling evidence that progesterone, in addition to estrogen, promotes breast tumorigenesis. In some human breast cell lines, there is a correlation between progesterone receptors and cell growth (39, 40) . Women on hormone replacement therapy that includes progestins exhibit a 7-to 13-fold increased mammographic-defined parenchymal density compared to conjugated estrogens alone (41) and a 4-fold increase in breast cancer risk compared to estrogen alone (42, 43) . The biological and molecular mechanisms responsible for the progesterone effects are unknown and likely to be complex.
The experiments described here examine the occurrence of aneuploidy in normal and tumorigenic mammary epithelial cells that are null for the tumor suppressor gene p53 and the role of ovarian steroid hormones in facilitating the frequency of aneuploidy. The results suggest that progesterone, not estrogen, stimulates aneuploidy in p53 null mammary cells.
MATERIALS AND METHODS

Transplantation
All mice were bred and maintained in a clean conventional mouse facility in the Center for Comparative Medicine at Baylor College of Medicine. The animals were maintained with unrestricted access to food and water under conditions of a 12/12 h light-dark cycle.
Donor mammary ducts were dissected from 7 to 10 wk old Balb/c p53 null female mice or p53 wild-type female mice and transplanted as ϳ1 mm 3 fragments into the cleared contralateral mammary fat pads of 3 wk old BALB/c p53 wild-type mice (44) . Two weeks after transplantation, some of the mice were exposed to chronic hormone treatment either via a pituitary isograft (45) or silastic tubing (46) containing estradiol 17B (50 g), progesterone (20 mg), or both hormones or remained untreated. After 4 -5 wk of hormone stimulation, the mammary glands were collected and evaluated for development in whole mount preparations (44) or prepared for primary cell culture (47) . Some of the mice were left undisturbed to be evaluated for proliferative/apoptotic indices at 10 wk or to develop tumors for subsequent chromosomal analysis. Each individual treatment group contained at least six fat pads. Experiments were performed either twice (estrogen, progesterone studies) or five times (pituitary isograft studies) and always included untreated p53 null mammary transplants.
The protocol for hormone exposure was based on the results of Guzman et al. (46) , who demonstrated that silastic tubing implants containing estrogen and progesterone deliver sustainable blood levels of these hormones equivalent to that found in midpregnancy. Previous studies have shown that a pituitary isograft under the kidney capsule generates elevated blood levels of prolactin and progesterone, but only slightly elevated blood levels of estrogen (45) .
The mammary tumors examined in this study were derived from mice bearing p53 null mammary cells that had been left untreated or were treated with a pituitary isograft or pituitary isograft and 7,12-dimethylbenzanthracene (DMBA) (30) .
Immunohistochemistry
For BrdU analysis of cell proliferation, mice were injected intraperitoneal (i.p.) with BrdU (70 mg/kg BW) and killed 2 h later. The no. 4 inguinal gland was fixed in Methacarn, processed, and evaluated for BrdU labeling index as described in ref 48 . There were 3-4 mice per group, and 500 cells from each gland were counted.
For the apoptosis index, standard hemotoxylin and eosinstained 4 m sections, adjacent to sections used for BrdU staining, were evaluated for apoptotic cells by morphological criteria as described and illustrated (49) . The apoptotic index is based on scoring 500 nuclei per gland.
Estrogen and progesterone receptors were evaluated as described in ref 50 . The rabbit anti-estrogen receptor IgG, MC-20, and rabbit anti-progesterone receptor IgG, C-19 (Santa Cruz Biotechnology, Inc., Santa Cruz, Calif.) were used at 1:200 dilution.
Chromosome analysis
Mice were anesthetized (Nembutal, injected i.p. at 80 mg/kg) and the no. 4 mammary glands were removed as described previously (51) . Epithelial cells suspensions were prepared using the protocol of Ethier et al. (52) with some modification. Briefly, glands were minced with scalpels and suspended in medium 199 containing type III collagenase (200 U/ml) and Dispase (1 mg/ml). The suspension was incubated at 37°C for 3 h with gentle agitation. The cells were then washed extensively with medium 199 and plated in 2% fetal bovine serum for 90 min to allow unwanted fibroblasts to attach. The supernatant containing epithelial cells was then collected and cells were counted as described previously (53) . After isolation, cells were seeded onto collagen-coated 60 mm dishes at densities of 1 ϫ 10 5 cells/dish. Cells were grown under 10% CO 2 in JRH Ham's F-12 medium supplemented with insulin, hydrocortisone, transferrin, epidermal growth factor, Fungizone, gentamicin, and 5% fetal bovine serum. The population doubling time for these cells was estimated to be 30 h. Cell populations were maintained in culture for 5 days, which was approximately four population doublings. Blind-coded chromosome preparations of the various populations were made as described previously (53) . Briefly, on the fifth day of culture, cell cultures were incubated in 0.1 g/ml Colcemid for 3 h. Cells were collected and metaphase spreads were made, stained with Giemsa after treatment with 0.1 M HCl at 55°C for 1 h, and chromosome numbers were recorded. A minimum of 50 metaphases were scored from each preparation.
Immunocytochemistry
For immunocytochemical staining, freshly isolated epithelial cells were grown on coverslips for 48 h. Cells were fixed in 4% paraformaldehyde in PEM buffer (80 mM Pipes, pH 7.0, 1 mM EGTA, 1 mM MgCl 2 ) for 15 min at room temperature. After fixation, cells were permeabilized in 0.5% Triton/PEM buffer for 5 min, washed for 15 min in PEM buffer, and incubated in blocking solution (PEM buffer with 5% goat serum) for 1 h at 37°C. Incubation of primary antibodies diluted in blocking buffer was carried out for 1 h at 37°C. We used a human autoantibody (a gift from J. B. Rattner) for centrosome staining (1:1000) and an ␣-tubulin specific antibody for microtubule staining (1:20) . Coverslips were washed three times in PEM buffer. The cells were then incubated with an Alexa 488-conjugated goat-anti-mouse (1:800) (Molecular Probes, Eugene, Oreg.) and a Texas red-conjugated goat anti-human antiserum (1:500) (Pierce, Rockford, Ill.). Nuclei were stained for 5 min in DAPI (10 g/ml) (Sigma, St. Louis, Mo.). Immunofluorescence microscopy was performed using a Deconvolution microscope (Applied Precision, Issaquah, Wash.) to collect images of single mitotic cells.
Confocal imaging and scoring of centrosomes
Mammary tumor tissue was embedded in cryo-gel and sectioned in 50 m using a minitome cryostat (23) . The thick frozen sections were mounted onto positively charged slides, fixed [4% formaldehyde in phosphate-buffered saline (PBS)] for 20 min, and permeabilized (0.05% Triton X-100 in PBS) for 5 min. Incubation with the primary antibody was performed overnight at 4°C in 1% bovine serum albumin in PBS. Subsequently, the preparations were washed for 1 h in PBS at RT and incubated with the secondary antibody at 37°C for 3 h. Tissue was stained with PI for 5 min, washed, and slides were mounted using Vecta shield as mounting media. Centrosomes were detected with a human anticentrosome autoantibody (1:1000) and nuclei were stained with propidium iodide (2 g/ml). Immunofluorescence microscopy was performed with a confocal microscope (Molecular Dynamics, Sunnyvale, Calif.; SARASTRO 2010). Scoring was accomplished by counting the number of stained nuclei and the corresponding number of centrosomes in sections of the tumor tissue. The number of centrosomes and nuclei were counted in adjacent 5 m optical sections in order to avoid double counting of individual cells. Counts were made on cells in the terminal ducts, alveolar buds, and the stroma. A minimum of 300 nuclei/sample were counted and plotted as number of centrosomes vs. percentage of cells.
RESULTS
Aneuploidy in normal and neoplastic p53 null mammary cells
Flow cytometric analysis of mammary tumors arising in p53 null mammary cells had increased DNA content, suggesting that a majority of such tumors were aneuploid. To verify this assumption, the chromosome distribution of six tumors arising in p53 null mice was examined in cells at metaphase. The results of these analyses are shown in Table 1 . Of six primary tumors arising 21-31 wk after transplantation of p53 null normal mammary cells into the cleared fat pads of wild-type Balb/c mice, all were markedly aneuploid (mean percent aneuploid cellsϭ72, mean chromosome numberϭ56), whereas normal mammary cells from p53 wild-type mice were diploid. An example of the chromosome distribution of one tumor arising in a pituitary isografted mouse is shown in Fig. 1A .
To determine the ploidy status of p53 null normal mammary cells, mammary epithelial cells were collected at 6 -7 wk after transplantation. The original donor mammary epithelium was from 7-10 wk old p53 null BALB/c female mice. As shown in Table 1 and Fig. 1B , the p53 null mammary epithelial cells taken from young mice were not aneuploid with respect to either percent of aneuploid cells or mean chromosome number. These two measurements were the same as measured in p53 wild-type mammary epithelial cells (Table 1, Fig. 1C ). In contrast, the same mammary epithelial cells transplanted into wild-type mice and subsequently hormonally stimulated for 4 or 5 wk with a pituitary isograft developed a striking increase in aneuploidy as measured by either mean percent aneuploid cells ϭ 51 or mean chromosome number ϭ 53 (Table 1, Fig. 1D ). The comparison of the p53 null untreated cells vs. the p53 null, hormone-stimulated cells was performed in five independent experiments, all of which yielded similar results.
Aneuploidy in p53 null normal mammary cells in untreated mice was found to increase with age. In two cases we serially transplanted p53 mammary cells for two consecutive transplant generations, so the chronological age of the mammary epithelial cells was 24 -26 wk when we collected and examined them for chromosome distribution. In these two cases, aneuploid cells comprised 20 and 30% of all cells with modal chromosome numbers of 49 and 40, respectively.
To ascertain any major morphological or biological alterations in p53 null mammary cells experiencing chronic hormone stimulation, we examined selected sets of developmental characteristics by whole mount preparations and immunohistochemical staining. Figure 2 demonstrates that the subgross morphology of the mammary gland in the virgin gland and the hormone-stimulated gland was identical for the p53 null and p53 wild-type glands under both developmental states. Table 2 demonstrates that differences in frequency of estrogen receptor and progesterone receptor-positive cells in the BrdUlabeling index and in apoptotic index were not detected between the p53 null and p53 wild-type cells in hormonally stimulated mice after 6 -10 wk of hormone stimulation.
Steroid hormone-induced aneuploidy
Pituitary isografted mice display markedly elevated blood levels of prolactin and progesterone and slightly elevated levels of estrogen (45) . To determine whether the steroid hormones were responsible for the increase in aneuploidy detected in pituitary isografted mice, we examined the effect of steroid hormones administered singly or combined on aneuploidy. Figure 3 illustrates the results of two experiments. p53 null mammary cells, but not wildtype cells, exposed to estrogen and progesterone for 4 -1/2 wk exhibited the same marked increase in aneuploidy as observed in p53 null cells exposed to hormones induced by a pituitary isograft. For hormones administered singly, progesterone but not estrogen markedly increased aneuploidy and to the same extent as the cells exposed to both hormones. Mammary cells exposed to progesterone and estrogen or just progesterone contained 38 -40% aneuploid cells, respectively. The progesterone exposed mammary cells demonstrated a large increase in tertiary ductal branching not observed in the estrogen-exposed cells (Fig. 4) .
Aneuploidy need not involve centrosome amplification
Primary tumors and cultured normal p53 null cells were examined for centrosomal amplification. Unlike results observed with fibroblasts from p53 null mice (22, 54) , the majority of the samples from the p53 null mammary epithelial cells from primary tumors (Fig. 5, Fig. 6) , untreated, or estrogen- progesterone-treated normal mammary gland did not exhibit an increase in centrosome amplification. Using confocal microscopy, we collected optical sections of p53 null tumors arising in untreated mice, p53 null tumors arising in hormonal stimulated mice (pituitary isografting) or after DMBA treatment, or the combination of both (hormone ϩ DMBA). Figure 5 shows the centrosome numbers in five primary tumors arising in p53 null mammary epithelium. Two tumors arising in pituitary isografted mice contained normal centrosome numbers (Fig. 6C) . One of these tumors had a DNA index of 1.6, with 32% of the cells being aneuploid. One tumor arising in mice treated with both a pituitary isograft and DMBA contained 12% of the cells, with more than two centrosomes (Fig. 6D) . This tumor had a diploid DNA content by flow cytometry. One of two tumors (Fig. 5) arising in untreated p53 null mice demonstrated 15% of the cells, with more than two centrosomes in cells surrounding a definable lumen [i.e., cells were organized as ducts (Fig. 6B) ], but only 2% of the cells exhibited abnormal centrosome number in cells that were organized as sheets (Fig. 6A) . This tumor was also diploid by flow cytometry analysis.
After 2 days in culture, normal mammary epithelial cells show a typical pattern of small islands. Cells were fixed and stained for centrosomes, microtubules, and DNA and images were collected using a Deconvolution microscope. Centrosomes were scored in two different sets of cultures. In the control group (p53 null transplant without hormonal stimuli), the distribution of centrosomes represents a population of normal growing cells: 67% of cells have one centrosome, 31% have two, and 2% have three centrosomes/cell (Fig. 7A) . The primary cell culture from the estrogen/progesterone-treated gland was similar to that of the untreated gland with respect to cell morphology and centrosome number, indicating that aneuploidy in the hormone-treated p53 null mammary cells was not mediated by centrosome amplification (Fig. 7B) .
DISCUSSION
Three results generated by these experiments are of general interest. One is the observation that progesterone was sufficient to facilitate aneuploidy in mammary cells. It has been firmly established that progesterone, as well as estrogen, is mitogenic for the mammary epithelial cells (31) (32) (33) (34) (35) . Progesterone is primarily important for tertiary side branching whereas estrogen is important for duct elongation. If progesterone-driven epithelial cell proliferation per se is the stimulus for the occurrence and accumulation of aneuploidy, then it is difficult to understand the different levels of aneuploidy found in cells experiencing estrogen and progesterone alone. Both are mitogenic hormones for the gland and stimulate proliferation over and above the basal growth rate occurring in transplanted epithelial cells. Three possible explanations are immediately apparent. First, the frequency of proliferation in progesterone-exposed cells must be significantly greater than in estrogen-exposed cells, resulting in an accumulation of aneuploid cells generated by chromosome missegregation occurring in mitosis. At this time we do not have results on the frequency of proliferation in progesterone and/or estrogen exposed cells at 1, 2, and 3 wk. Second, the mammary subpopulation responsive to progesterone might be different and more susceptible to chromosome missegregation than the cells responsive to estrogen. Some authors have suggested the presence of cells that localize to lateral branch points and are uniquely stimulated to proliferate by progesterone (34) . Third, an alternative hypothesis would state that progesterone alters the expression and/or function of critical proteins 
a Results are expressed as mean Ϯ standard error of the mean. There were no statistically significant differences among the four characteristics between the two groups of mammary epithelial cells. Figure 3 . Effect of steroid hormones on aneuploidy in p53 null mammary cells. Chromosome distribution of p53 null mammary epithelial cells exposed to estrogen or progesterone singly or in combination.
that regulate chromosome segregation. The possible candidates are numerous (14) , but the effect of progesterone on any of the possible candidates is unknown. Although it is known that estrogen can affect microtubules (11) , to our knowledge the effect of progesterone has not been reported. Whatever the mechanism, the data suggest a unique interaction between progesterone stimulation of mammary cells and the absence of p53. The absence of p53 per se does not alter the overall cell proliferation kinetics, apoptosis, or steroid receptor positivity of the mammary cells experiencing prolonged hormonal stimulation. This is in accordance with the results of Jerry et al. (29) that normal mammary gland development in the postpubescent or the pregnant mouse is not altered by the absence of p53.
The result that progesterone alone can facilitate aneuploidy may have greater importance with the recent publications that demonstrate women on hormone replacement treatments that include progesterone have increased mammographic breast density and increased breast cancer risk than women taking only estrogen (41) (42) (43) . The studies of aneuploidy in mouse cells and the human epidemiological studies suggest that progesterone has unanticipated deleterious effects on mammary epithelial cells. Although we have reported that prolonged hormonal exposure (i.e., progesterone and prolactin) provided by a pituitary isograft strongly enhances tumorigenesis in the p53 null mammary cells, similar experiments with progesterone alone remain to be performed. In summary, the accumulated recent results warrant a better understanding of progesterone on mammary cell biology and function. Second, the presence of a normal chromosome distribution in less than 16 wk old p53 null mammary epithelial cells indicates that aneuploidy or chromosomal instability is not rampant in all somatic cells that have lost p53. This result is in contrast to the studies of Fukasawa et al. (22, 54) , who demonstrated that fibroblasts and hematopoietic cells obtained from p53 null mice demonstrated a high frequency of chromosome instability. The experiments of Fukasawa et al. (22, 54) differ from the experiments reported here in at least two fundamental ways. Most important, the cell types are dissimilar. The biology of epithelial cells differs in multiple ways from mesenchymal cells and it is likely that extrinsic and intrinsic regulatory pathways differ for mitogenesis. It is well established that in vitro assays for transformation of fibroblast cells are not always applicable to mammary epithelial cells (55, 56) , suggesting that the two cell types differ in factors and/or pathways that regulate growth control and cell-cell and cell-substrate interactions. Furthermore, the major cell type neoplastically transformed in p53 null mice is of mesenchymal origin (20) , not ectodermal or endodermal, again suggesting that cells of mesenchymal origin are at increased risk.
It is also worthwhile to note that the cell culture conditions used in experiments by Fukasawa et al. (22) were different from the short-term primary cultures of the mammary cells. Passage 2 cells were used in their original studies (22) . This is important because mouse fibroblasts in culture are genetically unstable and aneuploidy can arise within a few passages (57) . In the more recent experiment (54), passage 0 cells were used; however, the protocol required a period of growth followed by 60 h without growth factors, then 15 h of medium with growth factors to restimulate growth before metaphase cells were collected. Finally, it should be noted that Tsukada et al. (58) reported that cloned fibroblasts from p53 null mice were highly diploid and had a normal karyotype. They concluded that chromosomal changes were not essential for an enhanced proliferative potential. Tsukada et al. (58) also examined mammary epithelial cells that exhibited an enhanced proliferative potential in vitro and retained differentiated morphogenic potential in 3-dimensional cultures. The authors did not report on ploidy status of the mammary cells.
These results do not imply that chromosomal instability is absent in p53 null mammary cells. Several results suggest aneuploidy in mammary epithelial cells is a function of age and/or proliferation. Aneuploid mammary epithelial cells were observed in two cases where the donor cells were of chronological age equal to 24 -26 wk, as they had been transplanted in the mammary fat pad twice serially. The number of cell population doublings would have been even greater than that occurring in 24 wk old mammary gland that had not been transplanted, as each transplantation results in a round of extensive proliferation. Furthermore, hormones that induce proliferation enhance aneuploidy. Finally, mammary tumors were aneuploid. These results suggest that aneuploidy, as judged by chromosome gain or loss, is a function of age and/or proliferation history. It is feasible that age is a surrogate for proliferation history and that the mitotic machinery is the source of the genetic instability. Lengauer and co-workers suggest that the chromosomal missegregation rate is 10 Ϫ2 per chromosome per generation in the colorectal tumors exhibiting chromosomal instability (59) . Cells containing chromosomal missegregation would accumulate in p53 null cells undergoing extensive proliferation.
A third result of interest is the role of centrosome amplification as one mechanistic basis for aneuploidy. The precedents for this mechanistic defect are the observations that p53 null fibroblasts exhibit a high frequency of centrosome abnormalities coincident with aneuploidy (22, 54) and the frequent occurrence of centrosome abnormalities in tumor cells (25) (26) (27) (28) . The results presented here suggest that centrosome amplification need not be coincident with aneuploidy as neither p53 null normal diploid cells nor p53 null hormone-stimulated cells (estrogen plus progesterone) showed detectable amplification. These results are in accord with recent observations that centrosome amplification is not a frequent event in a p53 null mouse mammary epithelial cell line (Murphy and Rosen, personal communication). These results do not rule out the possibility that centrosome abnormalities in mammary epithelial cells may contribute to tumorigenesis in some instances. Centrosome numbers were amplified in some but not all mammary tumors. Amplified centrosomes were correlated with the formation of structurally and functionally aberrant mitotic spindles (Goepfert and Medina, unpublished observation).
In summary, the results of these experiments suggest that specific hormone combinations will enhance aneuploidy and subsequently tumorigenesis in normal mammary epithelial cells that have lost p53 gene function. In view of the recent reports indicating the increased risk for breast cancer in women taking progesterone in hormone replacement therapy, the mechanisms of progesterone action in normal mammary cell growth and function deserve more intense investigation.
